Success Metrics

Clinical Success Rate
84.6%

Based on 11 completed trials

Completion Rate
85%(11/13)
Active Trials
3(16%)
Results Posted
64%(7 trials)
Terminated
2(11%)

Phase Distribution

Ph phase_4
2
11%
Ph phase_1
5
26%
Ph phase_2
3
16%
Ph phase_3
7
37%

Phase Distribution

5

Early Stage

3

Mid Stage

9

Late Stage

Phase Distribution17 total trials
Phase 1Safety & dosage
5(29.4%)
Phase 2Efficacy & side effects
3(17.6%)
Phase 3Large-scale testing
7(41.2%)
Phase 4Post-market surveillance
2(11.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

84.6%

11 of 13 finished

Non-Completion Rate

15.4%

2 ended early

Currently Active

3

trials recruiting

Total Trials

19

all time

Status Distribution
Active(4)
Completed(11)
Terminated(2)
Other(2)

Detailed Status

Completed11
unknown2
Recruiting2
Terminated2
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
19
Active
3
Success Rate
84.6%
Most Advanced
Phase 4

Trials by Phase

Phase 15 (29.4%)
Phase 23 (17.6%)
Phase 37 (41.2%)
Phase 42 (11.8%)

Trials by Status

unknown211%
not_yet_recruiting15%
recruiting211%
completed1158%
active_not_recruiting15%
terminated211%

Recent Activity

Clinical Trials (19)

Showing 19 of 19 trials
NCT05179876Phase 3

A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option

Recruiting
NCT04175600Phase 3

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

Active Not Recruiting
NCT04914247

Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease

Unknown
NCT07356375

Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension

Not Yet Recruiting
NCT01106014Phase 3

Selexipag (ACT-293987) in Pulmonary Arterial Hypertension

Completed
NCT03496506Phase 1

A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects

Completed
NCT04565990Phase 3

A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study

Completed
NCT03078907Phase 4

Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.

Completed
NCT02558231Phase 3

The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension

Completed
NCT02260557Phase 2

Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis

Completed
NCT02206295Phase 1

Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg

Completed
NCT02770222Phase 1

A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects

Completed
NCT05825417Phase 4

Pulmonary Hypertension: Intensification and Personalisation of Combination Rx

Recruiting
NCT03689244Phase 3

A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment

Terminated
NCT03942211Phase 2

A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag

Terminated
NCT04589390Phase 2

Selexipag for the Treatment of Schistosomiasis-Associated Pulmonary Arterial Hypertension

Unknown
NCT02471183Phase 3

Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension

Completed
NCT02791815Phase 1

Potential Pharmacokinetic Interaction Between Selexipag and Midazolam in Healthy Male Subjects

Completed
NCT02206204Phase 1

Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects

Completed

All 19 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
19